60 Degrees Pharmaceuticals Reports Q2 Loss, Cash Runway Through Early October
SXTP is trading near its 52-week low of $1.05 (11% above the low).
Summary
60 Degrees Pharmaceuticals reported a Q2 net loss of $2.27 million and disclosed cash sufficient only through early-October 2026, raising substantial doubt about its ability to continue as a going concern.
Key Events · Earnings and Guidance · SXTP
-
Going Concern Warning
Cash of $1.02 million as of June 30, 2026, with projected runway only through early-October 2026. Management states substantial doubt about the company's ability to continue as a going concern.
-
Material Weaknesses Persist
Three material weaknesses in internal control over financial reporting remain unremediated as of June 30, 2026, including inadequate policies, lack of documentation, and access control issues.
-
Nasdaq Listing Risk
Stockholders' equity of $2,614,185 is barely above the $2,500,000 minimum required by Nasdaq Listing Rule 5550(b)(1), with continued losses threatening compliance.
-
Subsequent Financing
July 2026 PIPE offering raised $739,809 net, and Knight Therapeutics converted 8,400 Series A preferred shares into 658,629 common shares, further diluting existing holders.
Analysis · SXTP · Life Sciences
The 10-Q reveals a critical cash runway of only through early-October 2026, with substantial doubt about the company's ability to continue as a going concern. Material weaknesses in internal controls remain unremediated, and stockholders' equity is barely above Nasdaq's minimum requirement. The subsequent July 2026 PIPE offering raised only $739,809 net, providing limited runway extension.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 37.1% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SXTP was trading at $1.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1M. The 52-week trading range was $1.05 to $8.62. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.